Malaria Initiative (commonly referred to as PMI ) will not be possible without the development and scale-up of new health technologies designed for use in low-resource settings, which are needed to address both long-standing endemic diseases and prepare for potential pandemic threats. (8) Public funding has proven highly successful at incentivizing the development of health technologies for global health that are high-impact, accessible, and cost-saving. (9) COVID–19 has demonstrated the importance of global access to health technologies designed for low-resource settings. (10) Support for the development of accessible health technologies for low-resource settings can have reciprocal value and produce tools that reduce health care costs, improve public health, and strengthen health security for the United States. (11) For decades, the United States Agency for International Development has been a catalyst in the global health innovation ecosystem. While other Federal departments and agencies, including the National Institutes of Health, the Centers for Disease Control and Prevention, and the Department of Defense, provide support for global health technologies, the United States Agency for International Development is the only Federal agency that provides broad support for the late-stage development of new health technologies to combat neglected tropical diseases and emerging infectious diseases and other health conditions for low-resource settings specifically. (12) While the need for new tools to tackle disease threats has grown, in recent years, investments by the United States Agency for International Development in research and development have shrunk as a proportion of its overall global health spending, squeezed by both stagnant budgets and growing needs. (13) Innovation at the United States Agency for International Development is primarily supported from siloed disease- and population-specific appropriations accounts, resulting in the limitation of its ability to seek shared value across health sectors or